GLP-1 Drugs Linked to Fewer Surgeries and Less Medication in Hidradenitis Suppurativa Patients
A Danish nationwide study finds HS patients use GLP-1 receptor agonists earlier and more often, with reduced surgical burden post-initiation.
Summary
Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease strongly tied to obesity, metabolic syndrome, and cardiovascular disease — all central aging concerns. A large Danish registry study tracked over 12,500 HS patients from 2000 to 2022, comparing GLP-1 receptor agonist (GLP-1RA) use against psoriasis patients and general population controls. HS patients started GLP-1RA therapy more frequently (8.2% vs. 5.7% and 3.2%) and earlier than the other groups. After initiating GLP-1RA treatment, HS patients showed reductions in antibiotic use and disease-related surgical procedures. However, similar reductions were observed in matched HS patients who did not start GLP-1RA treatment, meaning the differences were not statistically significant. The findings highlight a growing real-world intersection between GLP-1 drugs and inflammatory skin disease but stop short of confirming a direct therapeutic effect.
Detailed Summary
Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease causing painful nodules and draining sinus tracts in skin folds. Beyond its dermatological burden, HS is tightly linked to obesity, insulin resistance, type 2 diabetes, and cardiovascular disease — a metabolic profile that places it squarely in the domain of age-related chronic disease. As GLP-1 receptor agonists (GLP-1RAs) like semaglutide surge in use for obesity and metabolic disorders, understanding how they interact with inflammatory conditions like HS has become a pressing clinical question.
This nationwide Danish register-based cohort study included 12,581 adults with HS, matched against 9,824 psoriasis patients and 12,581 general population controls, covering the period from January 2000 to December 2022. Researchers examined GLP-1RA initiation rates, timing, comorbidity burden, healthcare utilization, and treatment patterns during the two years before and after GLP-1RA initiation.
Patients with HS initiated GLP-1RA treatment more frequently (8.2%) than psoriasis patients (5.7%) and controls (3.2%), and they did so significantly earlier — a mean of 8.88 years from diagnosis, compared to over 10 years for the other groups. Cardiometabolic and psychiatric comorbidities increased in all groups between diagnosis and GLP-1RA initiation, underscoring the progressive metabolic deterioration common in HS. After starting GLP-1RA therapy, HS patients showed lower rates of surgical procedures and reduced systemic medication use, including antibiotics.
Critically, comparable reductions were observed in matched HS non-users over the same timeframe, and the between-group differences did not reach statistical significance. This limits conclusions about causality.
For clinicians and longevity-focused practitioners, these findings highlight a meaningful real-world convergence between metabolic pharmacotherapy and inflammatory skin disease management. GLP-1RAs are already proven tools for cardiometabolic risk reduction — a core longevity target. Whether they also directly modulate HS disease activity requires prospective randomized trials. Summary is based on the abstract only.
Key Findings
- HS patients initiated GLP-1RA therapy more than twice as often as general population controls (8.2% vs. 3.2%).
- HS patients started GLP-1RA treatment nearly 1.5 years earlier than psoriasis patients and controls.
- Surgical procedures and systemic medication use declined after GLP-1RA initiation in HS patients.
- Similar declines were seen in matched HS non-users, so differences were not statistically significant.
- Cardiometabolic and psychiatric comorbidities rose progressively from HS diagnosis to GLP-1RA initiation.
Methodology
Nationwide Danish register-based cohort study covering 2000–2022, including 12,581 HS patients matched by age and sex to psoriasis patients and general population controls. Healthcare utilization, surgical procedures, and medication use were assessed two years before and after GLP-1RA initiation. Matched non-initiators served as a comparison group for post-initiation trends.
Study Limitations
The study is observational and register-based, preventing causal inference about GLP-1RA effects on HS disease activity. Comparable trends in matched non-initiators suggest confounding by time or regression to the mean rather than a drug effect. The full study is not open access; this summary is based on the abstract only.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: